Compare Sun Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs FULFORD INDIA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA FULFORD INDIA SUN PHARMA/
FULFORD INDIA
 
P/E (TTM) x 86.1 398.8 21.6% View Chart
P/BV x 3.7 6.2 59.1% View Chart
Dividend Yield % 0.6 0.1 683.8%  

Financials

 SUN PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
FULFORD INDIA
Mar-14
SUN PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs484942 51.4%   
Low Rs315450 70.0%   
Sales per share (Unadj.) Rs136.9691.4 19.8%  
Earnings per share (Unadj.) Rs17.511.5 152.3%  
Cash flow per share (Unadj.) Rs26.015.4 169.3%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %1.00.3 348.3%  
Book value per share (Unadj.) Rs188.7380.0 49.6%  
Shares outstanding (eoy) m2,399.263.90 61,519.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x2.91.0 290.1%   
Avg P/E ratio x22.960.7 37.7%  
P/CF ratio (eoy) x15.445.3 33.9%  
Price / Book Value ratio x2.11.8 115.7%  
Dividend payout %22.917.4 131.4%   
Avg Mkt Cap Rs m958,8642,714 35,325.1%   
No. of employees `00017.80.4 3,999.8%   
Total wages/salary Rs m63,624505 12,598.7%   
Avg. sales/employee Rs Th18,490.66,073.0 304.5%   
Avg. wages/employee Rs Th3,582.61,137.4 315.0%   
Avg. net profit/employee Rs Th2,357.6100.7 2,341.7%   
INCOME DATA
Net Sales Rs m328,3752,696 12,178.3%  
Other income Rs m6,360125 5,071.6%   
Total revenues Rs m334,7352,822 11,862.5%   
Gross profit Rs m69,898-46 -150,641.4%  
Depreciation Rs m20,52815 135,051.3%   
Interest Rs m3,02710 31,866.3%   
Profit before tax Rs m52,70254 97,057.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,6060-   
Tax Rs m8,22810 85,708.3%   
Profit after tax Rs m41,86845 93,664.2%  
Gross profit margin %21.3-1.7 -1,237.0%  
Effective tax rate %15.617.7 88.3%   
Net profit margin %12.81.7 769.1%  
BALANCE SHEET DATA
Current assets Rs m316,5421,738 18,209.8%   
Current liabilities Rs m157,064545 28,835.0%   
Net working cap to sales %48.644.3 109.7%  
Current ratio x2.03.2 63.2%  
Inventory Days Days8848 180.6%  
Debtors Days Days1054 2,432.7%  
Net fixed assets Rs m243,10212 2,042,874.8%   
Share capital Rs m2,39939 6,152.1%   
"Free" reserves Rs m450,2451,443 31,202.0%   
Net worth Rs m452,6451,482 30,542.8%   
Long term debt Rs m20,2890-   
Total assets Rs m682,5252,077 32,865.8%  
Interest coverage x18.46.7 274.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.3 37.1%   
Return on assets %6.62.6 252.0%  
Return on equity %9.23.0 306.7%  
Return on capital %11.24.3 260.9%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m74,21917 431,504.1%   
Fx outflow Rs m27,964673 4,154.1%   
Net fx Rs m46,255-656 -7,051.5%   
CASH FLOW
From Operations Rs m65,54890 72,830.8%  
From Investments Rs m-25,888105 -24,749.9%  
From Financial Activity Rs m-57,151-14 405,329.1%  
Net Cashflow Rs m-13,857181 -7,677.0%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 3.8 135.0%  
FIIs % 23.0 0.1 23,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.2 39.2%  
Shareholders   133,026 4,783 2,781.2%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Zoomed 613 Points Today(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 18, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS